Dr PBN Prasad To Hold Charge As DCGI On Temporary Basis

New Delhi  (ANI): Dr PBN Prasad will hold the charge of the post of Drugs Controller General of India from February 16 to 28 this year or until further orders, an official notice said on Wednesday.

According to the official notice issued by Dr Kiran Kumar Karlapu, Deputy Secretary to the Government of India, “It has been decided with the approval of the Competent Authority, that Dr PBN Prasad, JDC(I) shall hold the charge of the post of Drug Controller of (India) under FR 49(v)wef 16.02.2023 till 28.02.2023 (date of his superannuation) or until further orders, whichever is earlier.”

Recently, UPSC recommended the name of Dr Rajeev Singh Raghuvanshi as the new Drugs Controller General of India (DCGI).

The Union Public Service Commission (UPSC) conducted interviews for the appointment of the DCGI last week. The top contenders were Dr VG Somani, Dr Rajeev Singh Raghuvanshi and Dr Jai Prakash. According to the sources soon final name will be announced.

Earlier in November last year, Dr V G Somani’s term as Drugs controller general of India (DCGI) was extended for three months that came into effect from November 16 last year. This was done the second time, however, earlier he got an extension in the month of August 22.

Dr Kiran Kumar Karlapu, Deputy Secretary, Department of Health and Family Welfare issued the circular regarding the extension of DCGI for a further period of three months.

Dr V G Somani was appointed as Drugs Controller General of India in the month of August 2019, DCGI heads the Central Drugs Standard Control Organisation (CDSCO) which is responsible for ensuring quality drug supply across the country. It also has the authority to give approval to new drugs and regulate clinical trials. (ANI)

  • Related Posts

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Obesity drug market to gain as Indians pop the pill and Chinese bring more

    Obesity drug market to gain as Indians pop the pill and Chinese bring more

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Boehringer Ingelheim launches AI centre for pharma research in London

    Boehringer Ingelheim launches AI centre for pharma research in London

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March